An observational study in ANCA-associated Vasculitis, Granulomatosis With Polyangiitis and Microscopic Polyangiitis, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Completed at 9 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational
The goal of this multicentre observational study is to compare the safety and effectiveness of rituximab biosimilars to the originator in Canadian patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), two main forms of ANCA-associated vasculitis (AAV).
The main questions it aims to answer are:
Investigators will perform study assessments (including recording disease activity, damage, and adverse events) at the time of participants' usual clinical care visits, at regular intervals for 2 years after starting rituximab (for induction or maintenance treatment) or switching from an originator to a biosimilar as part of their usual care.
Researchers will compare outcomes among participants who have received rituximab originators (from 2018 onwards) or biosimilars as part of their usual care, to see if there are differences in relapses, remission rates, damage, serious infections, serious adverse events, and treatment approval wait times.
Background. Rituximab (RTX), a B-cell depleting therapy, has comparable efficacy to cyclophosphamide for induction of remission in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and superior efficacy to azathioprine for maintenance of remission (1,2). RTX is now a first-line therapy for remission induction and maintenance of remission in severe GPA and MPA (3).
Biosimilar RTX agents are molecules that are highly similar in structure to the 'originator' RTX that was initially studied and approved for the treatment of AAV. Among patients with rheumatoid arthritis, randomized controlled trials have demonstrated comparable efficacy and safety between originator and RTX biosimilars (4,5). Extension studies found that switching from originator to biosimilar does not alter disease activity, immunogenicity, or safety (6,7). Conversely, data on the outcomes of RTX biosimilars in AAV are limited. A retrospective study from Korea included 26 patients (\~80% MPA) who received either Truxima (n=15) or Mabthera/Rituxan (n=11) for second-line induction after failure or intolerance to cyclosphosphamide (CYC) (8). There were no obvious deviations in relapse, mortality, end-stage kidney disease, or cardiovascular outcomes compared to other studies with similar populations. A second study was a retrospective cohort study of 77 patients with GPA in India who received RTX biosimilars not available in Canada (Reditux, Rituxipca, Mabtas) for induction, maintenance, or both (9). Outcomes were comparable to those observed in randomized controlled trials of the originator drug.
Despite this scarce amount of data, many Canadian provincial and private funders are mandating the use of biosimilar agents (e.g. Truxima, Ruxience, Riximyo) for induction and maintenance of GPA and MPA, in place of the originator drug (Rituxan). There is a need for longitudinal prospective studies to determine comparative safety and effectiveness of RTX biosimilar agents in Canadian patients with GPA or MPA.
The COVID-19 pandemic has raised concerns for patients and providers about the safety of immunosuppression with RTX. Cohort studies of patients with rheumatic disease have reported an association between RTX and the risk of severe COVID-19 and death from COVID-19 (10-12). Rituximab may also reduce the immunogenicity, and thus the effectiveness, of COVID-19 vaccination, as has been observed for other vaccines (13).
Objectives. The overarching objective of this study is to compare the real-world safety and effectiveness of originator and biosimilar RTX for the treatment of GPA/MPA.
Specific objectives:
To determine, in patients with GPA/MPA receiving biosimilar or originator RTX for remission induction and/or maintenance:
Participant recruitment:
Potential prospective participants meeting inclusion criteria will be identified by clinicians providing care to patients with GPA or MPA (i.e., the local study investigators) when patients attend their routine clinical care visits (in-person or telemedicine). The local study investigators (i.e. the clinician providing care to the patient) will then describe the study to potential participants, and if interested, will be given the informed consent form to read (in paper or electronic format, per the potential participant's wishes). The potential participant will have the opportunity to ask any questions to the clinician/investigator or research coordinator, who will be the person obtaining consent. The potential participant will also have the option of reading the consent form at a later date, and will be given the contact information of the study coordinator should he/she wish to notify the investigator and/or coordinator of his/her intent to participate at a later date.
Informed consent Informed consent will be obtained either electronically (via the secure REDCap platform) or using paper consent forms during usual care visits. Patients' participation is entirely voluntary. Prospective participants will provide informed consent to participate in the study and may discontinue their participation at any time.
This study will be conducted in accord with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (2018), as well as in respect of the requirements set out in the applicable standard operation procedures of the Research Institute of the McGill University Health Centre Research Institute and of the McGill University Health Centre Research Ethics Board. The McGill University Health Centre Research Ethics Board has reviewed this study and is responsible for monitoring it at all participating institutions in the health and social services network in Québec. Each participating center outside the Réseau de la Santé et des Services Sociaux has approval from their local Research Ethics Board.
Data Collection
Participants will be followed for 24 months.
The following will be collected at enrolment/baseline:
Subsequent study assessments Data collection/study visits will occur at Months 3 (+/-1) (RTX induction recipients only) , 6(+/-3), 12(+/-3), and 24(+/-6), coinciding with usual practice clinical care visits.
At these visits, the following information will be recorded, based on physician clinical assessments (participant history, physical exam), and medical chart reviews (outcome definitions are described in Outcomes):
Data will be collected and entered into secure electronic data capture (REDCap) and/or through paper Case Report Forms (for centers without access to REDCap), and subsequently entered centrally in the main study REDCap database.
As this study will be conducted during the COVID-19 pandemic, virtual visits instead of in-person visits will be accepted as they represent the frequent usual care at the time of this pandemic.
Study size rational:
Planned enrollment will be 120 RTX biosimilar users and 120 RTX originator users, either prospectively or from existing registries with retrospective collection, over the course of 18 months, across 8 different participating centres. This study size would provide 80% power (at a significance level of 0.05) to show a 2-fold increase in the percentage with relapses in the biosimilar group, assuming 15% have a relapse at 24 months in the originator group.
Significance Currently very limited data exist on comparative safety or effectiveness of RTX biosimilars versus the originator drug in ANCA-associated vasculitis. This study will provide real-world data on patients receiving either RTX originator or biosimilar for induction or maintenance of GPA or MPA to permit these comparisons.
Funding The study is funded by the Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM). CAN-AIM has a mandate to compare safety and effectiveness of originator and biosimilar drugs across diseases and disciplines. The study is also funded by the Canadian Initiative for Outcomes in Rheumatology cAre (CIORA), which ultimately aims to improve the care of Canadians diagnosed with a rheumatic disease.
157 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 75 are open to participants now.
This study's enrollment of 201 is above the median of 120 across 35 observational studies indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 421 studies on the registry; 105 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients aged ≥18 with a diagnosis of GPA or MPA who initiated rituximab (RTX) originator or biosimilar within the last 6 months at the time of enrolment, OR who belong to prospective longitudinal registries and initiated RTX originator or biosimilar after 2018 and > 6 months before enrolment. The limit of January 2018 was chosen to keep the historical cohort as contemporary as possible and limit measurement bias regarding study outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prospective cohort:
Initiated within the last 6 months:
Historical cohort:
Followed in a prospective longitudinal cohort study/registry within the CanVasc network, and initiated the following after January 1, 2018 but >6 months prior to study enrollment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients aged ≥18 with a diagnosis of GPA or MPA treated with rituximab (RTX) originator for induction and/or maintenance.
Patients aged ≥18 with a diagnosis of GPA or MPA treated with RTX biosimilars (e.g. Ruxience, Truxima, Riximyo, etc) for induction and/or maintenance.
Proportion of participants with a relapse
Relapse will be defined as active disease in any organ system (BVAS v3\>0) after remission had previously been achieved AND need to escalate glucocorticoids (GC) to ≥20 mg/day OR change immunosuppression, including receiving RTX infusion earlier than planned/higher dose than planned The proportion of participants with relapses at 6 months will be compared between groups.
Time frame: 6 months
Time to relapse
Relapse will be defined as active disease in any organ system (BVAS v3\>0) after remission had previously been achieved AND need to escalate glucocorticoids (GC) to ≥20 mg/day OR change immunosuppression, including receiving RTX infusion earlier than planned/higher dose than planned. Survival analyses will compare time to disease relapse between originator and biosimilar recipients, adjusting for potential confounders
Time frame: From Month 0 until date of first relapse, assessed up to 24 months
Proportion of participants with a major relapse
Major relapse will be defined as any relapse with one or more of the BVAS/WG major items: gangrene, scleritis, retinal exudates/hemorrhage, sensorineural deafness, mesenteric ischemia, alveolar hemorrhage, respiratory failure, urinary red blood cell casts, rise in creatinine \>30% or fall in creatinine clearance \>25%, meningitis, cord lesion, stroke, cranial nerve palsy, sensory peripheral neuropathy, motor mononeuritis multiplex The proportion of participants with a major relapse at 6 months will be compared between groups.
Time frame: 6 months
Proportion in clinical remission 6 months post-induction
Assessed in subgroup receiving RTX induction. Clinical remission will be defined as absence of disease activity in any organ system (BVAS v3=0)
Time frame: 6 months
Proportion with a Serious Adverse Event (SAE)
SAE will be defined as any medical event, not necessarily causally related to the treatment, that requires inpatient hospitalization, prolongation of hospitalization, causes a congenital malformation, results in significant disability or incapacity, that is life threatening or that results in death. Sensitivity analysis will exclude hospitalizations due to disease relapse as SAEs. The proportion of participants with \>=1 SAE will be compared between groups at 6 months.
Time frame: 6 months
Proportion with a Serious Infection (SI)
SI will be defined as any infection requiring intravenous (IV) antibiotics, or resulting in hospitalization, prolonging hospitalization, or death The proportion of participants with \>=1 SI will be compared between groups at 6 months. Survival analyses will compare time to SI between biosimilar and originator groups, adjusting potential confounders and stratifying by RTX exposure type (induction only vs induction + maintenance).
Time frame: 6 months
Wait time (days) from RTX application to approval and first infusion
Among participants newly starting RTX for induction or maintenance, mean wait time from RTX application to approval and infusion will be compared between originator and biosimilar groups using multiple linear regression, adjusting for potential confounders. Secondary analyses will stratify outcomes according RTX exposure category (RTX induction only, RTX induction followed by RTX maintenance, RTX maintenance without RTX induction).
Time frame: 6 months
Change in Vasculitis Damage Index (VDI)
Vasculitis damage will be measured with the Vasculitis Damage Index (VDI). Change in VDI over time will be compared between groups using linear mixed effects models for repeated measures, overall and according RTX exposure category (RTX induction only, RTX induction followed by RTX maintenance, RTX maintenance without RTX induction).
Time frame: From Baseline (Month 0) to 6 months
Proportion with a Relapse
Relapse will be defined as active disease in any organ system (BVAS v3\>0) after remission had previously been achieved AND need to escalate glucocorticoids (GC) to ≥20 mg/day OR change immunosuppression, including receiving RTX infusion earlier than planned/higher dose than planned. The proportion of participants with \>=1 relapse at 24 months will be compared between originator and biosimilar recipients.
Time frame: 24 months
Proportion with Major relapse
Major relapse will be defined as any relapse with one or more of the BVAS/WG major items: gangrene, scleritis, retinal exudates/hemorrhage, sensorineural deafness, mesenteric ischemia, alveolar hemorrhage, respiratory failure, urinary red blood cell casts, rise in creatinine \>30% or fall in creatinine clearance \>25%, meningitis, cord lesion, stroke, cranial nerve palsy, sensory peripheral neuropathy, motor mononeuritis multiplex The proportion of participants with \>=1 major relapse at 24 months will be compared between originator and biosimilar groups.
Time frame: 24 months
Proportion with a Serious Adverse Event (SAE)
SAE will be defined as any medical event, not necessarily causally related to the treatment, that requires inpatient hospitalization, prolongation of hospitalization, causes a congenital malformation, results in significant disability or incapacity, that is life threatening or that results in death. Sensitivity analysis will exclude hospitalizations due to disease relapse as SAEs. The proportion of participants with \>=1 SAE will be compared between groups at 24 months.
Time frame: 24 months
Proportion with a Serious Infection (SI)
SI will be defined as any infection requiring intravenous (IV) antibiotics, or resulting in hospitalization, prolonging hospitalization, or death The proportion of participants with \>=1 SI will be compared between groups at 24 months.
Time frame: 24 months
Proportion needing to discontinue RTX due to treatment failure
Treatment failure is defined as rituximab cessation due to an adverse event or relapse. The proportion discontinuing RTX due to treatment failure (due to adverse events or relapse) will be compared between groups.
Time frame: 24 months
Change in Vasculitis Damage Index (VDI)
Vasculitis damage will be measured with the Vasculitis Damage Index (VDI). Change in VDI over time will be compared between groups using linear mixed effects models for repeated measures, overall and according RTX exposure category (RTX induction only, RTX induction followed by RTX maintenance, RTX maintenance without RTX induction).
Time frame: From Baseline (Month 0) to 24 months
Time to major relapse
Major relapse will be defined as any relapse with one or more of the BVAS/WG major items: gangrene, scleritis, retinal exudates/hemorrhage, sensorineural deafness, mesenteric ischemia, alveolar hemorrhage, respiratory failure, urinary red blood cell casts, rise in creatinine \>30% or fall in creatinine clearance \>25%, meningitis, cord lesion, stroke, cranial nerve palsy, sensory peripheral neuropathy, motor mononeuritis multiplex Survival analyses will compare time to major relapse between originator and biosimilar recipients.
Time frame: From Month 0 until date of first major relapse, assessed up to 24 months
Time to Serious Adverse Event (SAE)
SAE will be defined as any medical event, not necessarily causally related to the treatment, that requires inpatient hospitalization, prolongation of hospitalization, causes a congenital malformation, results in significant disability or incapacity, that is life threatening or that results in death. Sensitivity analysis will exclude hospitalizations due to disease relapse as SAEs. Survival analyses will compare time to SAE between exposure groups, adjusting for potential confounders
Time frame: From baseline (Month 0) until date of first SAE, assessed up to 24 months
Time to Serious Infection (SI)
SI will be defined as any infection requiring intravenous (IV) antibiotics, or resulting in hospitalization, prolonging hospitalization, or death Survival analyses will compare time to SI between biosimilar and originator groups, adjusting potential confounders and stratifying by RTX exposure type (induction only vs induction + maintenance).
Time frame: From baseline (Month 0) until date of first SI, assessed up to 24 months
Time to RTX discontinuation due to treatment failure
Treatment failure is defined as rituximab cessation due to an adverse event or relapse. Survival analyses will compare time to RTX discontinuation due to adverse event or relapse between originator and biosimilar groups.
Time frame: From Month 0 until date of first relapse, assessed up to 24 months
COVID-19 infections
Rates of COVID-19 infections will be assessed among participants treated with RTX from September 2019 onwards (either originator or biosimilar, induction or maintenance), overall and stratified by vaccination status
Time frame: 6 months
COVID-19 hospitalizations
Rates of COVID-19 hospitalizations at 6 months will be assessed among participants treated with RTX from September 2019 onwards (either originator or biosimilar, induction or maintenance), overall and stratified by vaccination status
Time frame: 6 months
COVID-19 infections
Rates of COVID-19 infections will be assessed among participants treated with RTX from September 2019 onwards (either originator or biosimilar, induction or maintenance), overall and stratified by vaccination status
Time frame: 24 months
COVID-19 hospitalizations
Rates of COVID-19 hospitalizations at 24 months will be assessed among participants treated with RTX from September 2019 onwards (either originator or biosimilar, induction or maintenance), overall and stratified by vaccination status
Time frame: 24 months
Symptomatic late onset neutropenia (LON)
Symptomatic late onset neutropenia (LON) is defined as neutropenia associated with fever OR infection where no other explanation is found (LON typically occurs a month after the RTX infusion, and is most often totally asymptomatic). Crude event rates of LON will be calculated by dividing the number of events during follow-up by the corresponding person-time at risk.
Time frame: 24 months
Symptomatic hypogammaglobulinemia
Symptomatic hypogammaglobulinemia is defined as infection associated with hypogammaglobulinemia (IgG \< local laboratory limit). Crude event rates of symptomatic hypogammaglobulinemia in each exposure group will be calculated by dividing the number of events during follow-up by the corresponding person-time at risk.
Time frame: 24 months
Plan to share: Undecided
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis →
McGill University Health Centre/Research Institute of the McGill University Health Centre →